10:36:12 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-05-12 Ordinarie utdelning ATANA 0.00 SEK
2025-05-09 Kvartalsrapport 2025-Q1
2025-05-09 Årsstämma 2025
2025-02-21 Bokslutskommuniké 2024
2024-11-22 Kvartalsrapport 2024-Q3
2024-08-16 Kvartalsrapport 2024-Q2
2024-05-03 Kvartalsrapport 2024-Q1
2024-05-03 Årsstämma 2024
2024-02-23 Bokslutskommuniké 2023
2023-10-27 Kvartalsrapport 2023-Q3
2023-08-18 Kvartalsrapport 2023-Q2
2023-05-08 Ordinarie utdelning ATANA 0.00 SEK
2023-05-05 Kvartalsrapport 2023-Q1
2023-05-05 Årsstämma 2023
2023-02-24 Bokslutskommuniké 2022
2022-12-07 Extra Bolagsstämma 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-08-19 Kvartalsrapport 2022-Q2
2022-05-09 Ordinarie utdelning ATANA 0.00 SEK
2022-05-06 Kvartalsrapport 2022-Q1
2022-05-06 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-17 Kvartalsrapport 2021-Q2
2021-05-10 Ordinarie utdelning ATANA 0.00 SEK
2021-05-07 Kvartalsrapport 2021-Q1
2021-05-07 Årsstämma 2021
2021-02-25 Bokslutskommuniké 2020
2020-11-27 Kvartalsrapport 2020-Q3
2020-11-09 Extra Bolagsstämma 2020
2020-08-27 Kvartalsrapport 2020-Q2
2020-05-11 Ordinarie utdelning ATANA 0.00 SEK
2020-05-08 Kvartalsrapport 2020-Q1
2020-05-08 Årsstämma 2020
2020-02-24 Bokslutskommuniké 2019
2019-11-29 Kvartalsrapport 2019-Q3
2019-08-09 Extra Bolagsstämma 2019
2019-08-07 Kvartalsrapport 2019-Q2
2019-05-08 Ordinarie utdelning ATANA 0.00 SEK
2019-05-07 Kvartalsrapport 2019-Q1
2019-04-05 Årsstämma 2019
2019-02-26 Bokslutskommuniké 2018
2018-05-08 Ordinarie utdelning ATANA 0.00 SEK
2018-05-07 Årsstämma 2018
2018-02-22 Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaNordic SME Sweden
SektorHälsovård
IndustriLäkemedel & Handel
Attana bedriver forskning och utveckling av läkemedel. Bolaget specialiserar sig inom biologisk interaktionskarakterisering, som används för analys i utvecklandet av nya läkemedel. Bolagets patenterade lösningar används vid studerandet av bindningsegenskaper och makrostrukturer i celler, proteiner, virus och bakterier. Verksamhet återfinns främst inom Norden och Europa. Bolaget grundades under 2002 och har sitt huvudkontor i Stockholm.
2023-11-20 11:55:44

During the pandemic it has been observed that individuals react very differently to be infected by the virus and to the vaccination. A few individuals obtain very strong protection against the wild type (the original Wuhan) and the mutated variants, whereas others obtain less good protection. This paper in Nature Communications (https://www.nature.com/articles/s41467-023-42408-x) focus on characterizing the neutralization capacity (protection) of antibodies from convalescent COVID-19 individuals against SARS-CoV-2 virus. Using Attana technology, kinetic characterization of the antibody-spike interaction reveals that the antibodies with the best kinetics properties are the same ones that provides the that the strongest neutralizing capacity. For Attana these results are yet another independent research publication with results that supports our concept of immunity profiles where kinetic interaction properties are used to determine how well protection an individual has to a given pathogen.

The uniqueness of this paper is the combination of many different technologies and that the studies have been performed at experimentally challenging but physiologically more relevant conditions than previously published results. For instance, have the effect of glycosylation of the spike mutations and the importance of the dynamics of the interaction been included. Overall, this resulted in that the antibodies from convalescent individuals could be divided into weak, moderate, and strong neutralizers.

Attana QCM technology has been applied to study the interaction kinetics of the different antibodies.  High affinity binding in the sub-nM range with slow dissociation rates were observed. The association-dissociation kinetics clearly indicate stable binding of the antibodies to the Spike trimer. In the neutralization experiments the highest neutralization was observed for the two antibodies CoVA2-39 and 5A6. These two antibodies have the fastest association rate, being 1.25*106mol/s and 1.18*106mol/s respectively.

Association rates in the magnitude of 106mol/s has in several previous studies using Attana technology been observed to correlate with strong neutralization, e.g. for SARS-CoV-2, dengue, hepatis B, tetanus, and tuberculosis. In correlation with the dissociation rate, this is used as criteria's in Attana's immunity profiles, where kinetic interaction properties are used to determine how well protection an individual has to a given pathogen. Consequently, this study forms a good reference for the application of Attana technology and kinetic characterization as a mean for determine neutralizing capacity.

[En bild som visar text, diagram, Teckensnitt, linje

Automatiskt genererad beskrivning]

Attana QCM kinetic evaluation of the interactions between Spike and SARS CoV-2 antibodies